[
    [
        {
            "time": "",
            "original_text": "医药生物行业：20Q2主动公募医药持仓维持大幅超配状态 重仓集中度有所下降",
            "features": {
                "keywords": [
                    "医药生物",
                    "20Q2",
                    "主动公募",
                    "超配",
                    "重仓集中度"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业：20Q2主动公募医药持仓维持大幅超配状态 重仓集中度有所下降",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药拟A+H股上市，近千亿元市值仍难跻身CRO第一梯队",
            "features": {
                "keywords": [
                    "泰格医药",
                    "A+H股上市",
                    "市值",
                    "CRO",
                    "第一梯队"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药拟A+H股上市，近千亿元市值仍难跻身CRO第一梯队",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药拟上市 近千亿元市值仍难跻身CRO第一梯队",
            "features": {
                "keywords": [
                    "泰格医药",
                    "上市",
                    "市值",
                    "CRO",
                    "第一梯队"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药拟上市 近千亿元市值仍难跻身CRO第一梯队",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]